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Conclusions: All the treatment plans could meet the clinical therapy 
needs. The dose measurements also showed good agreement with 
computed doses. RapidArc technique can treat patients with advanced 
NPC effectively, with good target coverage and sparing of critical 
structures. RA has a slightly dosimetric superiority than RA-FFF. 
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Purpose/Objective: To quantify positional variation of the anal canal 
and inguinal lymph nodes and derive the required CTV-to-PTV 
margins. 
Materials and Methods: Ten anal cancer patients were included in 
this retrospective study, 5 male and 5 female. All patients were 
treated prone using a feet cushion to maintain a stable positioning of 
the legs over the course of treatment. In male patients, the penis and 
testicles were lifted using a scrotum holder to avoid contact between 
the target volume and these healthy tissues. Cone Beam CT scans 
were made daily prior to treatment for the first 3 fractions, and 
weekly thereafter, in the context of an offline shrinking action level 
(SAL) setup correction protocol. A total of 95 CBCT were made and 
registered to the planning CT scan.  
Setup errors were measured by evaluating the chamfer match of the 
pelvic bones. The 'organ motion' of the inguinal lymph nodes and the 
anal canal relative to the pelvic bony anatomy were measured by grey 
value registration of these structures (see figure). CTV-to-PTV margins 
were calculated based on an offline correction protocol and assuming 
a 4 mm delineation uncertainty according to: M=2.5Σ+0.7σ. 
 
  
Figure. Coronal view of the four region of interests used for 
registration; a) pelvic bones, b) inguinal lymph nodes right, c) inguinal 
lymph nodes left and d) anal tumor. 
Results: Group mean (GM), systematic error (Σ) and random error (σ) 
of the 'organ motion' of the inguinal lymph nodes and the anal canal 
are given in the table. Required CTV-to-PTV margins assuming an 
offline SAL protocol with the pelvic bones as surrogate for the 
treatment volume are also shown in the table. Margins for a pelvic 
bone online correction protocol were identical as the contribution of 
the setup error was negligible. 
 
  
Table. The Group Mean (GM), systematic error (Σ) and random error 
(σ) of the 'organ motion' of the inguinal lymph nodes right (r) and left 
(l) and the anal canal (CTV) and the margins required for an offline 
registration protocol.  
Conclusions: This study indicates that standard clinical CTV-to-PTV 
margins of 1cm and/or the registration protocol should be adjusted to 
deliver 95% of the prescribed dose to the CTV/lymph nodes for 90% of 
the patients. Adaptive radiotherapy enables compensation for the 
(differential) systematic errors of both the CTV and lymph nodes, 
allowing margins reduction.  
   
 SYMPOSIUM: EARLY BIOMARKERS FOR LATE EFFECTS 
IN DAILY PRACTICE  
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What more natural than a stress response that would vary among 
individuals? The individual factor has been pointed out in numerous 
medical research areas. The idea that each individual shows a specific 
response to radiation, like face to any stress, is well-accepted by 
public, but neither taken into account into radioprotection 
recommendations nor in a systematic process of prediction in 
radiotherapy or chemotherapy. However, to date, there is much 
evidence that about 5-15% individuals are radiosensitive i.e 
susceptible to adverse tissue reactions and/or radiation-induced 
cancer. Besides, the confusion between these last two notions due to 
toxicity and cancer proneness, respectively has not facilitated the 
prediction of patients at risk. Indeed, the long quest of "the" 
predictive assay still meet technical artefacts, cell types 
specificities, lacks in the understanding of the molecular and cellular 
responses and fashion effects. The major approaches to predict 
radiosensitivity are functional assays (notably DNA repair and signaling 
pathways), gene expression assay and detection of polymorphisms 
(SNP). Considering that there is a continuum in the radio-responses 
(i.e. radiosensitivity is not an all-or-none phenomenon), it is hard to 
imaging one SNP responsible for all the radiosensitivities and one SNP 
for each radiosensitivity, inasmuch as SNP may also depend on the cell 
and tissue type. Considering that few genes show a dose-dependent 
response with the same rate as cell death or mutagenesis, it is also 
difficult to identify "the" gene expression that would predict all the 
radiosensitivity. Conversely, results of nearly 40 years of research, 
functionnal assays of repair or signalling pathways of DNA damage, 
especially DNA double-strand breaks (DSB) are promising yet because 
some quantitative correlations has been demonstrated between 
clinical, cellular and molecular features, whatever the dose.  
Unfortunately, the methodology and the endpoints that would predict 
radiosensitivity are still to be determined. Here, we propose a 
classification of radiosensitivity based on the kinetics of the radiation-
induced nucleo-shuttling of the ATM protein. 
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Radiogenomics is the whole genome application of radiogenetics, 
which studies the influence of genetic variation on radiation response. 
Work in the area focuses on uncovering the underlying common 
genetic causes of individual variation in sensitivity to radiation, which 
is important for effective, safe treatment. Many radiogenomics 
studies published to-date, have used a candidate gene approach; i.e. 
genes thought to be involved in radiotherapy toxicity are studied. 
Such genetic associations have proved difficult to replicate. More 
recently studies have used a genome-wide approach, where the whole 
genome is screened for genetic variations associated with 
radiotherapy toxicity. GWAS studies of radiotherapy toxicity have 
shown evidence that genetic variations that are associated with late 
radiotherapy toxicity exist. Power calculations from such GWAS 
suggest that future studies should include more than 2500 
participants. Meta-analysis of GWAS studies in the radiogenomics 
consortium is currently underway to achieve such numbers. Continuing 
recruitment of patients into studies within the Radiogenomics 
Consortium is essential so that sufficiently powered studies can be 
performed, and methodological challenges addressed. 
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Purpose/Objective: Parametrial boost (PB) is used in advanced cancer 
cervix to increase the dose in regions where contribution from 
intracavitary brachytherapy (IC BT) is insufficient. Midline block is 
then used to protect midline organs at risk (OAR). However as stated 
by IAEA (2010), the efficacy of parametrial boosts has not been 
systematically tested and there is little literature evidence to support 
its routine use. 
An alternative technique for parametrial boosting is the combined 
intracavitary and interstitial (IC/IS) BT. The purpose of our study is to 
evaluate the dose delivered by IC BT and PB and compare it to IC/IS 
BT.  
Materials and Methods: We evaluated 51 consecutive patients with 
parametrial involvement at diagnosis. At BT 23 patients had persistent 
parametrial involvement necessitating combined IC/IS BT. For the 23 
patients we compared optimised IC BT combined with external beam 
PB field to the delivered optimised IC/IS BT. Whole pelvis conformal 
EBRT 45-50 Gy /25-30 fx and PDR BT 15-17.5 Gy x 2fx IC/IS was 
delivered. PB field was created as an external beam AP/PA field of 9 
Gy / 5fx, with midline block conformed to the isodose line 85 Gy and 
of at least 4 cm width. For the PB scenario summation of doses from 
EBRT plus an optimised IC BT plan and PB fields were used. The 
physical 3D dose distribution was converted to the EQD2 using α/β = 
10 Gy for tumour, and = 3 Gy for OAR with T½ = 1.5 hr. DVH 
parameters obtained in total EQD2 were GTV, HR CTV, IR CTV: D90, 
D100 and D2cm3for rectum, bladder, sigmoid and bowel. 
Testing the impact of organ movement was done by shaking the EQD2 
dose map 1 cm bilaterally and reading out the DVH parameters. 
The normal tissue volume irradiated to 60 Gy EQD2 (total EBRT+BT) 
was measured.  
Results: Table 1 shows mean total EQD2+SD (Gy) of IC+PB versus IC/IS 
BT. With IC+PB, 3 patients had < 79 Gy to the HR CTV D90 while IC/IS 
resulted in doses >84Gy for all patients. Comparing the target dose 
delivered by the shifted dose map to PB resulted in a difference of 1.0 
± 1.8 Gy for HR CTV D90, and - 1.0 ± 1.8 Gy for IR CTV D90. OAR D2cm3 
changed by 0.8 ± 1.3 Gy, 0.7 ± 1.0, 0.4 ± 2.6 Gy and 0.1 ± 2.8 Gy for 
bladder, rectum, sigmoid and bowel respectively. 
The PB resulted in a significantly higher V60 as compared to the IC/IS: 
For the IC/IS technique the mean V60 was 228.4 ± 81.5 cm3 and for 
the IC + PB it was 593.5 ±595.6 cm3 (p= 0.004). 
 
  
Conclusions: Midline blocked fields significantly increases dose by 5-9 
Gy to the D2cm3 of the rectum, sigmoid, bladder and bowel as 
compared to IC/IS, but was robust in terms DVH parameters for the 
'shaked' EQD2 dose map. Mean HR CTV D90 were comparable for both 
techniques, however PB resulted in significant underdosage for 3 
cases. With EBRT PB, large volume is irradiated to at least 60 Gy 
which may result in increased clinical morbidity expressed by this 
irradiated bowel and normal tissue. IC/IS compared to IC + PB spares 
better the OAR and deliver a more conformed RT to the targeted area 
with less normal tissue volume receiving 60Gy. 
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Purpose/Objective: In radiotherapy for cervix cancer elective and 
pathological lymph nodes (LN) in the pelvis, abdomen and inguinal 
regions are irradiated to a certain dose during external beam 
radiotherapy (EBRT).  
However the LNs will also receive a fraction of dose during 
brachytherapy (BT).  
This study aims to 1) evaluate the BT dose contribution to LN groups, 
2) compare LN doses from standard non-optimised PDRBT and 
optimised MRI guided PDR BT. 
Materials and Methods: 25 consecutive patients who received whole 
pelvis 3D conformal EBRT (45-50Gy in 25 or 30 fractions) and 2 
fractions of MRI guided PDR BT (each 15 or 17.5Gy) were analysed. LN 
groups were delineated as follows: para-aortic (PAN), common (CI), 
external (EI) and internal (II) iliac, obturator (OB), inguinal (ING), and 
presacral (PS). For each group D98%, D50% and D2% for full optimised 
BT were compared to those forstandard non-optimised BT. BT dose 
was normalised to a 2Gy fraction size (EQD2) using the linear 
quadratic model (α/β=10Gy, T1/2=1.5h). Correlation between TRAK 
and dose was assessed for all LNs with linear regression. 
Results: As shown in table 1 BT contributed with considerable dose 
(mean D50% was 3.8-6.2Gy) to the pelvic LNs (EI, II, OB, PS) in 
optimised plans. Less dose contribution was seen in CI, PAN (mean 
D50% was 0.5-1.9 Gy) and ING (1.5 Gy). Large inter-patient variation 
was seen with SDs of up to 2.6 Gyof D50%. For non-optimised BT D50% 
doses to PAN, CI and ING ranged from 0.6 to 2.7 Gy and to pelvic LN it 
ranged from 4.1 to 6.4 Gy.As shown in Table 1, a generally smaller 
dose to different LN-stations was delivered by the optimised plan 
compared to the standard plan. This is compatible to the efforts of 
creating a more conformal BT with dose optimisation. However, 
although differences were statistically significant for most LNs, they 
only amounted toa mean of 0.2 - 0.9 Gy (D50%). This difference can 
be explained by the overall reduction of the TRAK in the optimised 
plan by 0.25cGy±0.3 (p=0.0005) compared to the standard BT plan. 
This also explains the higher dose reduction (appr25%) to the 
abdominal LN group, compared to the LN dose reduction in the pelvic 
area close to HR - CTV (appr 10%). The dwell positions in the tip of the 
tandem are not used to the same degree in the optimised plan as in 
the standard plan,where all the positions are equally loaded. 
